常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.36/-21.39
|
|
企业价值
5.38M
|
| 资产负债 |
|
每股账面净值
4.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.94M
|
|
每股收益
1.47
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 15:48 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease. |

1.705 
